基本信息
浏览量:88
职业迁徙
个人简介
I am currently a group leader in the Translational Cancer and Immunity Center at the Qatar Biomedical Research Institute in Doha, Qatar and hold an assistant professor position at the College of Health and Life Sciences at the Hamad Bin Khalifa University in Qatar. I obtained my Ph.D. in Medical Sciences in 2003 at the Catholic University of Leuven (KULeuven, Belgium), focusing on the clinical utility of tumor and circulating proteases as novel biomarkers for breast cancer. Following my PhD, I undertook a postdoctoral position at the University of East Anglia (UEA, UK) where I studied the biological role and prognostic potential of several protease families in cancer.
My research interests focus on key areas that can help accelerate research in the breast cancer and infectious disease fields, and advance the development of new biomarkers and treatments. Part of my cancer research efforts focus on tumor-associated Cancer Testis Antigens (CTAs) as cancer biomarkers, novel therapeutic targets and immunomodulatory regulators in breast cancer, with a special emphasis on triple negative breast cancer. At the interface between cancer and infectious disease research, my group investigates disease-associated dysregulation of the host immune response and associated biomarkers and targets.
HONORS AND AWARDS
Open Initiative Award 2020, Qatar National Library, Qatar
Recognition for excellence 2016, Cancer Biology and Therapeutics Program (HMS-CBT), Harvard Medical School, USA.
HBKU Thematic Research Grant Program, “Validation of LDHC as a novel target for precision medicine in breast cancer”. Lead PI, 2021-2023.
QBRI Internal Grant Program (IGP), “Exploration of novel therapeutic opportunities targeting LDHC in triple negative breast cancer”. Lead PI, 2021-2024.
QBRI Interdisciplinary research program (IDRP), “Integrative, translational research against COVID-19”. Lead PI, 2021-2023.
QBRI Internal Grant Program (IGP), “Mechanisms in pancreatic development and breast cancer stemness mitigated by Sox2”. Co-PI, 2021-2024.
“How beta cell-derived interleukin-33 shapes T cell regulation in T1D”. Co-PI (2020-2023).
QBRI Interdisciplinary research program (IDRP), “Diagnostic and predictive biomarkers in breast cancer”. Co-PI, 2019-2024.
QBRI Interdisciplinary research program (IDRP), “An integrated -omic approach to identify biomarkers for Type 2 Diabetes associated complications and comorbidities”. Co-PI, 2018-2023.
QBRI Interdisciplinary research program (IDRP), “Identifying Potential Molecular Biomarkers for Autism Spectrum Disorder”. Co-PI, 2018-2023.
QBRI Internal Grant Program (IGP #2016-003), “Pilot study of the role of Lactate Dehydrogenase C (LDHC) in the growth and migratory potential of triple negative breast cancer cells”. Lead PI, 2017-2019.
QBRI Internal Grant Program (IGP #2014-006), “Cancer Testis Antigens as candidate targets for cancer immunotherapy of Triple Negative Breast Cancer and the role of hypoxia in T cell based immunotherapy. Lead PI, 2016-2019.
My research interests focus on key areas that can help accelerate research in the breast cancer and infectious disease fields, and advance the development of new biomarkers and treatments. Part of my cancer research efforts focus on tumor-associated Cancer Testis Antigens (CTAs) as cancer biomarkers, novel therapeutic targets and immunomodulatory regulators in breast cancer, with a special emphasis on triple negative breast cancer. At the interface between cancer and infectious disease research, my group investigates disease-associated dysregulation of the host immune response and associated biomarkers and targets.
HONORS AND AWARDS
Open Initiative Award 2020, Qatar National Library, Qatar
Recognition for excellence 2016, Cancer Biology and Therapeutics Program (HMS-CBT), Harvard Medical School, USA.
HBKU Thematic Research Grant Program, “Validation of LDHC as a novel target for precision medicine in breast cancer”. Lead PI, 2021-2023.
QBRI Internal Grant Program (IGP), “Exploration of novel therapeutic opportunities targeting LDHC in triple negative breast cancer”. Lead PI, 2021-2024.
QBRI Interdisciplinary research program (IDRP), “Integrative, translational research against COVID-19”. Lead PI, 2021-2023.
QBRI Internal Grant Program (IGP), “Mechanisms in pancreatic development and breast cancer stemness mitigated by Sox2”. Co-PI, 2021-2024.
“How beta cell-derived interleukin-33 shapes T cell regulation in T1D”. Co-PI (2020-2023).
QBRI Interdisciplinary research program (IDRP), “Diagnostic and predictive biomarkers in breast cancer”. Co-PI, 2019-2024.
QBRI Interdisciplinary research program (IDRP), “An integrated -omic approach to identify biomarkers for Type 2 Diabetes associated complications and comorbidities”. Co-PI, 2018-2023.
QBRI Interdisciplinary research program (IDRP), “Identifying Potential Molecular Biomarkers for Autism Spectrum Disorder”. Co-PI, 2018-2023.
QBRI Internal Grant Program (IGP #2016-003), “Pilot study of the role of Lactate Dehydrogenase C (LDHC) in the growth and migratory potential of triple negative breast cancer cells”. Lead PI, 2017-2019.
QBRI Internal Grant Program (IGP #2014-006), “Cancer Testis Antigens as candidate targets for cancer immunotherapy of Triple Negative Breast Cancer and the role of hypoxia in T cell based immunotherapy. Lead PI, 2016-2019.
研究兴趣
论文共 82 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Molecular Therapy: Oncologyno. 1 (2024): 200768-200768
FRONTIERS IN GENETICS (2024): 1378917-1378917
Cancer Researchno. 6_Supplement (2024): 7255-7255
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 4 (2024): 2247
Frontiers in oncology (2023): 1215332
Julie Decock,Ji-Rong Long,Ross C. Laxton,Xiao-Ou Shu,Conrad Hodgkinson,Wouter Hendrickx, Eve G. Pearce,Yu-Tang Gao, Andresa C. Pereira,Robert Paridaens,Wei Zheng,Shu Ye
crossref(2023)
Areej Mesleh,Hanan Ehtewish,Alberto de la Fuente, Hawra Al-Shamari,Iman Ghazal, Fatema Al-Faraj,Fouad Al-Shaban,Houari B Abdesselem,Mohamed Emara,Nehad M Alajez,Abdelilah Arredouani,Julie Decock,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn